Theravance Biopharma (TBPH): Increasing PT On Positive Pipeline Advancements - Guggenheim

September 19, 2016 6:47 AM EDT
Get Alerts TBPH Hot Sheet
Price: $36.07 -2.28%

Rating Summary:
    3 Buy, 1 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 15 | Down: 21 | New: 57
Trade TBPH Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Guggenheim analyst, Louise Chen, reiterated her Buy rating on shares of Theravance Biopharma (NASDAQ: TBPH) and raised the price target to $40 from $30 on an increase in the DCF's the terminal multiple to 7x from 5x.

New and positive advancements in TBPH's pipeline increased the analyst's confidence in the commercial opportunity for TBPH's therapy portfolio:

1) The company now has back-up compounds for its two flagship blockbuster drugs, TD-1473 and TD-0714

2) Additional FULFIL data at ERS supports the large market opportunity for the Closed Triple

3) GSK, TBPH's partner for the Closed Triple, has decided to develop the drug for asthma as well as COPD, which could nearly double the sales potential

For an analyst ratings summary and ratings history on Theravance Biopharma click here. For more ratings news on Theravance Biopharma click here.

Shares of Theravance Biopharma closed at $33.00 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Louise Chen, Guggenheim

Add Your Comment